$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 26 Oct 2016 | 20639 | In Stock
Related Topics: Drug , Protein

Introduction

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016’, provides in depth analysis on C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted pipeline therapeutics.

The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

- The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

- The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016

  • Table of Contents

    Table of Contents 2

    List of Tables 7

    List of Figures 8

    Introduction 9

    Global Markets Direct Report Coverage 9

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) Overview 10

    Therapeutics Development 11

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Stage of Development 11

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Therapy Area 12

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Indication 13

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Products Glance 15

    Late Stage Products 15

    Early Stage Products 16

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Companies 17

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Products under Development by Universities/Institutes 21

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment 23

    Assessment by Monotherapy/Combination Products 23

    Assessment by Mechanism of Action 24

    Assessment by Route of Administration 26

    Assessment by Molecule Type 28

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development 30

    AdAlta Pty Ltd. 30

    Ambrx, Inc. 31

    BioLineRx, Ltd. 32

    Bristol-Myers Squibb Company 33

    Eli Lilly and Company 34

    Globavir Biosciences, Inc. 35

    GlycoMimetics, Inc. 36

    Juventas Therapeutics, Inc. 37

    Pharis Biotec GmbH 38

    Polyphor Ltd. 39

    TaiGen Biotechnology Co., Ltd. 40

    Upsher-Smith Laboratories, Inc. 41

    X4 Pharmaceuticals, Inc. 42

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles 43

    AD-114 - Drug Profile 43

    Product Description 43

    Mechanism Of Action 43

    R&D Progress 43

    ALB-408 - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    AM-3114 - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    balixafortide - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    BL-8040 - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    burixafor - Drug Profile 58

    Product Description 58

    Mechanism Of Action 58

    R&D Progress 58

    GBV-4086 - Drug Profile 59

    Product Description 59

    Mechanism Of Action 59

    R&D Progress 59

    GMI-1359 - Drug Profile 60

    Product Description 60

    Mechanism Of Action 60

    R&D Progress 60

    HPH-112 - Drug Profile 62

    Product Description 62

    Mechanism Of Action 62

    R&D Progress 62

    HPH-196 - Drug Profile 63

    Product Description 63

    Mechanism Of Action 63

    R&D Progress 63

    HPH-211 - Drug Profile 64

    Product Description 64

    Mechanism Of Action 64

    R&D Progress 64

    hz-515H7 - Drug Profile 65

    Product Description 65

    Mechanism Of Action 65

    R&D Progress 65

    JVS-100 - Drug Profile 66

    Product Description 66

    Mechanism Of Action 66

    R&D Progress 66

    LY-2510924 - Drug Profile 71

    Product Description 71

    Mechanism Of Action 71

    R&D Progress 71

    Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile 74

    Product Description 74

    Mechanism Of Action 74

    R&D Progress 74

    POL-5551 - Drug Profile 75

    Product Description 75

    Mechanism Of Action 75

    R&D Progress 75

    Protein to Agonize CXCR4 for Inflammation - Drug Profile 76

    Product Description 76

    Mechanism Of Action 76

    R&D Progress 76

    PTX-9908 - Drug Profile 77

    Product Description 77

    Mechanism Of Action 77

    R&D Progress 77

    Q-122 - Drug Profile 78

    Product Description 78

    Mechanism Of Action 78

    R&D Progress 78

    Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile 80

    Product Description 80

    Mechanism Of Action 80

    R&D Progress 80

    Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile 81

    Product Description 81

    Mechanism Of Action 81

    R&D Progress 81

    Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 82

    Product Description 82

    Mechanism Of Action 82

    R&D Progress 82

    ulocuplumab - Drug Profile 83

    Product Description 83

    Mechanism Of Action 83

    R&D Progress 83

    USL-311 - Drug Profile 85

    Product Description 85

    Mechanism Of Action 85

    R&D Progress 85

    X-4P001 - Drug Profile 86

    Product Description 86

    Mechanism Of Action 86

    R&D Progress 86

    X-4P002 - Drug Profile 88

    Product Description 88

    Mechanism Of Action 88

    R&D Progress 88

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Projects 89

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products 94

    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Featured News & Press Releases 95

    Oct 14, 2016: AdAlta update on Orphan Drug Designation application for lead drug targeting idiopathic pulmonary fibrosis 95

    Oct 05, 2016: BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting 95

    Sep 27, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1b Study of X4P-001 in Patients with Resectable Stage III and Stage IV Melanoma 96

    Sep 20, 2016: BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA(pembrolizumab) for Treatment of Pancreatic Cancer 96

    Sep 12, 2016: AdAlta signs agreement with FujiFilm Diosynth Biotechnologies to begin manufacturing its lead fibrosis drug candidate 97

    Sep 08, 2016: BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference 98

    Sep 06, 2016: GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 99

    Jun 28, 2016: BioLineRx Announces Regulatory Submissions for Phase 2a Trial of BL-8040 in Combination with KEYTRUDA (pembrolizumab) for Treatment of Pancreatic Cancer 99

    May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 100

    May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 101

    May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 101

    May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 102

    Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 102

    Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 103

    Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML 104

    Appendix 107

    Methodology 107

    Coverage 107

    Secondary Research 107

    Primary Research 107

    Expert Panel Validation 107

    Contact Us 107

    Disclaimer 108

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20639 | GMDHC0614TDB

Number of Pages

108

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Type 2 Diabetes Mellitus: Update Bulletin [April 2016]
Introduction...Gain new KOL insights on the latest events that have the potential to impact the trea...
01 Apr 2016 by FirstWord Pharma USD $995 More Info
Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM):...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
NPS+ Type 2 Diabetes Mellitus (US)
IntroductionT2DM drug manufacturers: compare your brand to 7 major competitorsHow loyal are doctors ...
01 Dec 2015 by FirstWord Pharma USD $2,495 More Info
NPS+ Type 2 Diabetes Mellitus (EU5)
IntroductionT2DM drug manufacturers: Compare your brand to 7 major competitorsHow loyal are doctors ...
01 Dec 2015 by FirstWord Pharma USD $2,495 More Info
Medical Affairs Reputations (US): Type 2 Diabetes Mellitus
IntroductionWhat do physicians think of U.S. Medical Affairs teams in the Type 2 Diabetes Mellitus (...
01 Sep 2015 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations (EU5): Type 2 Diabetes Mellitus
IntroductionWhat do physicians think of Europe Medical Affairs teams in the Type 2 Diabetes Mellitus...
01 Sep 2015 by FirstWord Pharma USD $5,995 More Info
Type 2 Diabetes Mellitus: KOL Insight
IntroductionThe market for Type 2 Diabetes therapies is extremely crowded. Several classes, includin...
01 Jul 2015 by FirstWord Pharma USD $7,900 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)
IntroductionWhat environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? F...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)
IntroductionWhat market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to a...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...